3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
257
Carcinoma, Intraductal, Noninfiltrating
24
Breast Carcinoma In Situ
21
Neoplasms
12
Neoplasm Metastasis
12
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Medulloblastoma
2
Liver Neoplasms
2
Infertility
2
Interventions
Fulvestrant
10
Everolimus
6
Cetuximab
6
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled